FDA Approval in Multiple Myeloma, Priority Reviews in DLBCL and Myeloma, and More

FDA Approval in Multiple Myeloma, Priority Reviews in DLBCL and Myeloma, and More

Gina Columbus reports on the FDA approval in multiple myeloma, priority review designations in diffuse large B-cell lymphoma and multiple myeloma, a European approval in cutaneous T-cell lymphoma, and an acquisition of a major CAR T-cell therapy developer.